naftopidil has been researched along with Cancer of Prostate in 18 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "Silodosin has a greater impact on improving PI-induced lower urinary tract symptoms than the other two agents." | 9.15 | Comparison of prophylactic naftopidil, tamsulosin, and silodosin for 125I brachytherapy-induced lower urinary tract symptoms in patients with prostate cancer: randomized controlled trial. ( Baba, S; Fujita, T; Hayakawa, K; Ishiyama, H; Kimura, M; Kitano, M; Kotani, S; Matsumoto, K; Minamida, S; Satoh, T; Tabata, K; Tsumura, H, 2011) |
| "Silodosin has a greater impact on improving PI-induced lower urinary tract symptoms than the other two agents." | 5.15 | Comparison of prophylactic naftopidil, tamsulosin, and silodosin for 125I brachytherapy-induced lower urinary tract symptoms in patients with prostate cancer: randomized controlled trial. ( Baba, S; Fujita, T; Hayakawa, K; Ishiyama, H; Kimura, M; Kitano, M; Kotani, S; Matsumoto, K; Minamida, S; Satoh, T; Tabata, K; Tsumura, H, 2011) |
| " For bladder cancer cell lines used here such as 253J, 5637, KK-47, T24 and UM-UC-3 cells, prazosin, a selective α(1)-adrenoceptor blocker, reduced cell viability at concentrations more than 30 µmol/l." | 3.78 | Antitumor action of α(1)-adrenoceptor blockers on human bladder, prostate and renal cancer cells. ( Gotoh, A; Kanno, T; Nagaya, H; Nishizaki, T, 2012) |
| "Naftopidil and silodosin were administered 1 day after low-dose-rate brachytherapy, and were continued for at least 3 months." | 3.01 | Comparison of disease-specific quality of life in prostate cancer patients treated with low-dose-rate brachytherapy: A randomized controlled trial of silodosin versus naftopidil. ( Anai, S; Asakawa, I; Fujii, T; Fujimoto, K; Hasegawa, M; Maesaka, F; Miyake, M; Nakai, Y; Owari, T; Tanaka, N; Tomizawa, M; Yamaki, K, 2021) |
| "Naftopidil is used for benign prostatic hyperplasia management in Japan and a retrospective study brought out a reduced incidence of prostate cancer in patients that had been prescribed this drug." | 2.66 | Drug Repositioning of the α ( Florent, R; N'Diaye, M; Poulain, L, 2020) |
| "Naftopidil is a tubulin-binding drug with fewer adverse events, implying the usefulness of this drug in clinical applications when combined with DTX." | 1.48 | Additive naftopidil treatment synergizes docetaxel-induced apoptosis in human prostate cancer cells. ( Arima, K; Ishii, K; Kajiwara, S; Kanda, H; Kato, M; Matsuoka, I; Miki, M; Sasaki, T; Shiraishi, T; Sugimura, Y, 2018) |
| "Naftopidil seems to reduce prostate cancer incidence, possibly by inducing apoptosis, preferentially in cancer cells, and blocking transforming growth factor-β signaling." | 1.39 | Reduction of prostate cancer incidence by naftopidil, an α1 -adrenoceptor antagonist and transforming growth factor-β signaling inhibitor. ( Enomoto, Y; Fujimura, T; Fukuhara, H; Hirano, Y; Homma, Y; Kumano, S; Kume, H; Nishimatsu, H; Suzuki, M; Yamada, D, 2013) |
| "In naftopidil-treated PrSC, total interleukin-6 protein was significantly reduced with increased suppression of cell proliferation." | 1.37 | Naftopidil, a selective {alpha}1-adrenoceptor antagonist, suppresses human prostate tumor growth by altering interactions between tumor cells and stroma. ( Arima, K; Hori, Y; Ishii, K; Iwamoto, Y; Kanda, H; Kise, H; Nishikawa, K; Soga, N; Sugimura, Y, 2011) |
| "Hormone refractory prostate cancer was not found 1 year after the start of treatment." | 1.34 | [Giant prostate carcinoma treated effectively with endocrine therapy: case report]. ( Hasegawa, Y; Masue, N, 2007) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (16.67) | 29.6817 |
| 2010's | 11 (61.11) | 24.3611 |
| 2020's | 4 (22.22) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, H | 3 |
| Xu, F | 1 |
| Liang, X | 1 |
| Xu, BB | 1 |
| Yang, ZL | 1 |
| He, XL | 1 |
| Huang, BY | 1 |
| Yuan, M | 2 |
| Yu, YZ | 1 |
| Tian, XM | 1 |
| Wang, CL | 1 |
| Qian, YN | 1 |
| Deng, ZA | 1 |
| Zhang, JX | 1 |
| Lv, DJ | 1 |
| Zhang, HB | 1 |
| Shen, JL | 1 |
| Zhao, SC | 1 |
| Kadono, Y | 1 |
| Qian, Y | 1 |
| Jia, H | 1 |
| Yu, Y | 1 |
| Zhang, H | 1 |
| Shen, J | 1 |
| Zhao, S | 1 |
| Florent, R | 1 |
| Poulain, L | 1 |
| N'Diaye, M | 1 |
| Maesaka, F | 1 |
| Tanaka, N | 2 |
| Nakai, Y | 1 |
| Asakawa, I | 2 |
| Tomizawa, M | 1 |
| Owari, T | 1 |
| Miyake, M | 2 |
| Anai, S | 2 |
| Yamaki, K | 1 |
| Fujii, T | 1 |
| Hasegawa, M | 2 |
| Fujimoto, K | 2 |
| Ishii, K | 4 |
| Matsuoka, I | 1 |
| Kajiwara, S | 2 |
| Sasaki, T | 1 |
| Miki, M | 2 |
| Kato, M | 2 |
| Kanda, H | 4 |
| Arima, K | 4 |
| Shiraishi, T | 2 |
| Sugimura, Y | 4 |
| Chen, IJ | 1 |
| Murtola, TJ | 1 |
| Yamada, D | 1 |
| Nishimatsu, H | 1 |
| Kumano, S | 1 |
| Hirano, Y | 1 |
| Suzuki, M | 1 |
| Fujimura, T | 1 |
| Fukuhara, H | 1 |
| Enomoto, Y | 1 |
| Kume, H | 1 |
| Homma, Y | 1 |
| Torimoto, K | 1 |
| Hirayama, A | 1 |
| Konishi, N | 1 |
| Iwamoto, Y | 2 |
| Ishizaka, K | 1 |
| Machida, T | 1 |
| Tanaka, M | 1 |
| Kawamura, N | 1 |
| Nakamura, K | 1 |
| Kihara, K | 1 |
| Hori, Y | 1 |
| Nishikawa, K | 1 |
| Soga, N | 1 |
| Kise, H | 1 |
| Tsumura, H | 1 |
| Satoh, T | 1 |
| Ishiyama, H | 1 |
| Tabata, K | 1 |
| Kotani, S | 1 |
| Minamida, S | 1 |
| Kimura, M | 1 |
| Fujita, T | 1 |
| Matsumoto, K | 1 |
| Kitano, M | 1 |
| Hayakawa, K | 1 |
| Baba, S | 1 |
| Gotoh, A | 1 |
| Nagaya, H | 1 |
| Kanno, T | 1 |
| Nishizaki, T | 1 |
| Masue, N | 1 |
| Hasegawa, Y | 1 |
| Ogura, Y | 1 |
| Imamura, T | 1 |
| Kanai, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Prophylactic Versus Therapeutic Alpha-Blockers in Prostate Cancer Patients Undergoing Radical Course Radiation Therapy ± HDR Boost. A GROUQ Phase III Randomized Clinical Trial (PCS-VII).[NCT02220829] | Phase 3 | 188 participants (Anticipated) | Interventional | 2016-06-30 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for naftopidil and Cancer of Prostate
| Article | Year |
|---|---|
Drug Repositioning of the α
Topics: Adrenergic alpha-1 Receptor Antagonists; Antineoplastic Agents; Drug Repositioning; Humans; Male; Na | 2020 |
3 trials available for naftopidil and Cancer of Prostate
| Article | Year |
|---|---|
Comparison of disease-specific quality of life in prostate cancer patients treated with low-dose-rate brachytherapy: A randomized controlled trial of silodosin versus naftopidil.
Topics: Brachytherapy; Humans; Indoles; Male; Naphthalenes; Piperazines; Prostatic Neoplasms; Quality of Lif | 2021 |
Use of alpha-1 adrenoceptor antagonists in patients who underwent low-dose-rate brachytherapy for prostate cancer - a randomized controlled trial of silodosin versus naftopidil.
Topics: Adrenergic alpha-1 Receptor Antagonists; Aged; Aged, 80 and over; Brachytherapy; Humans; Indoles; Ma | 2014 |
Comparison of prophylactic naftopidil, tamsulosin, and silodosin for 125I brachytherapy-induced lower urinary tract symptoms in patients with prostate cancer: randomized controlled trial.
Topics: Adrenergic alpha-1 Receptor Antagonists; Aged; Analysis of Variance; Brachytherapy; Humans; Indoles; | 2011 |
14 other studies available for naftopidil and Cancer of Prostate
| Article | Year |
|---|---|
Design, synthesis and biological evaluation of novel arylpiperazine derivatives on human prostate cancer cell lines.
Topics: Antineoplastic Agents; Cell Proliferation; Drug Design; Drug Screening Assays, Antitumor; Humans; Ma | 2015 |
Synthesis and biological evaluation of arylpiperazine derivatives as potential anti-prostate cancer agents.
Topics: Androgen Receptor Antagonists; Antineoplastic Agents; Binding Sites; Cell Line, Tumor; Cell Prolifer | 2019 |
Editorial Comment to Comparison of disease-specific quality of life in prostate cancer patients treated with low-dose-rate brachytherapy: A randomized controlled trial of silodosin versus naftopidil.
Topics: Brachytherapy; Humans; Indoles; Male; Naphthalenes; Piperazines; Prostatic Neoplasms; Quality of Lif | 2021 |
Synthesis and pharmacological evaluation of naftopidil-based arylpiperazine derivatives containing the bromophenol moiety.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Drug Evaluation, Preclinical; Drug Scre | 2020 |
Additive naftopidil treatment synergizes docetaxel-induced apoptosis in human prostate cancer cells.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Growth Processes; Cell Line | 2018 |
Editorial comment from Dr Chen to reduction of prostate cancer incidence by naftopidil, an α1-adrenoceptor antagonist and transforming growth factor-β signaling inhibitor.
Topics: Adrenergic alpha-1 Receptor Antagonists; Humans; Male; Naphthalenes; Piperazines; Prostatic Neoplasm | 2013 |
Editorial comment from Dr Murtola to reduction of prostate cancer incidence by naftopidil, an α1-adrenoceptor antagonist and transforming growth factor-β signaling inhibitor.
Topics: Adrenergic alpha-1 Receptor Antagonists; Humans; Male; Naphthalenes; Piperazines; Prostatic Neoplasm | 2013 |
Reduction of prostate cancer incidence by naftopidil, an α1 -adrenoceptor antagonist and transforming growth factor-β signaling inhibitor.
Topics: Adrenergic alpha-1 Receptor Antagonists; Aged; Apoptosis; Cell Line, Tumor; HeLa Cells; Humans; Inci | 2013 |
Combination treatment with naftopidil increases the efficacy of radiotherapy in PC-3 human prostate cancer cells.
Topics: Adenocarcinoma; Animals; Cell Line, Tumor; Chemoradiotherapy; Combined Modality Therapy; Humans; Mal | 2017 |
Clinical efficacy of naftopidil on lower urinary tract symptoms after radical prostatectomy.
Topics: Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Dose-Response Relationship, Drug; Drug Admini | 2009 |
Naftopidil, a selective {alpha}1-adrenoceptor antagonist, suppresses human prostate tumor growth by altering interactions between tumor cells and stroma.
Topics: Adrenergic alpha-1 Receptor Antagonists; Animals; Apoptosis; Blotting, Western; Cell Proliferation; | 2011 |
Antitumor action of α(1)-adrenoceptor blockers on human bladder, prostate and renal cancer cells.
Topics: Adrenergic alpha-1 Receptor Antagonists; Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Hum | 2012 |
[Giant prostate carcinoma treated effectively with endocrine therapy: case report].
Topics: Adenocarcinoma; Adrenergic alpha-Antagonists; Aged, 80 and over; Androgen Antagonists; Anilides; Ant | 2007 |
Naftopidil, a selective alpha-1 adrenoceptor antagonist, inhibits growth of human prostate cancer cells by G1 cell cycle arrest.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Animals; Cell Line, Tumor; Ce | 2008 |